EuroEyes revenue grows, driven by presbyopia treatment demand

EuroEyes International Eye Clinic Limited reported a 2.4% increase in total revenue, reaching HK$377.1m for the six months ended June 30, 2025, primarily driven by robust growth in lens exchange surgeries. Lens exchange surgery revenue surged by 10.0% year-over-year to HK$218.6m, now accounting for 58.0% of total revenue, up from 54% in 2024. Combined with Presbyond surgery income, presbyopia correction treatments represent 62.7% of total revenue. Gross profit for the period rose by 5.9% year-on-year to HK$156.8m, with an associated gross profit margin of 41.6%.

The Group's EBITDA showed strong growth, increasing by 9.2% year-over-year to HK$131.8m. However, net profit attributable to equity holders decreased by 13.0% to HK$38.4m, largely due to a non-cash translation loss on Euro-denominated payables from the appreciation of the Euro against the Renminbi and Hong Kong Dollar. Germany remained the largest revenue contributor at HK$200.9m (53.3%), followed by PRC (HK$73.8m, 19.6%), the UK (HK$62.0m, 16.4%), and Denmark (HK$40.4m, 10.7%).

The company declared an interim dividend of HK$0.0315 per ordinary share, totaling approximately HK$10,102,239 for the six months ended June 30, 2025. EuroEyes' liquid assets included cash and cash equivalents of approximately HK$741.8m, denominated in EUR, HKD, RMB, GBP, and DKK.